Bridging lipid metabolism and innate host defense

Science Translational Medicine

Volumn 6, Issue 258, 2014, Pages 258fs41-

  Dos Santos, Claudia ^a   Marshall, John C ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CONVERTASE SUBTILISIN KEXIN TYPE 9; IMATINIB; LOW DENSITY LIPOPROTEIN RECEPTOR; SERINE PROTEINASE; TRASTUZUMAB; UNCLASSIFIED DRUG;

BACTERIAL INFECTION; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CYTOKINE RESPONSE; DEGRADATION KINETICS; GAIN OF FUNCTION MUTATION; GENE; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; INHIBITION KINETICS; INNATE IMMUNITY; LDLR GENE; LIPID METABOLISM; LOSS OF FUNCTION MUTATION; NONHUMAN; NOTE; OUTCOME ASSESSMENT; PCSK9 GENE; SEPSIS; SEPTIC SHOCK; SURVIVAL RATE; ANIMAL; IMMUNOLOGY; MALE; METABOLISM;

ANIMALS; HUMANS; IMMUNITY, INNATE; MALE; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; SHOCK, SEPTIC;

EID: 84908242470     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3010501     Document Type: Note

References (11)

1. T. I. Sørensen, G. G. Nielsen, P. K. Andersen, T. W. Teasdale, Genetic and environmental infl uences on premature death in adult adoptees. N. Engl. J. Med. 318, 727-732 (1988).
2. K. R. Walley, K. R. Thain, J. A. Russell, M. P. Reilly, N. J. Meyer, J. F. Ferguson, J. D. Christie, T.-a. Nakada, C. D. Fjell, S. A. Thair, M. S. Cirstea, J. H. Boyd, PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci. Transl. Med. 6, 258ra143 (2014).
3. K. M. Azzam, M. B. Fessler, Crosstalk between reverse cholesterol transport and innate immunity. Trends Endo-crinol. Metab. 23, 169-178 (2012).
4. J. Seok et al., Infl ammation and Host Response to Injury, Large Scale Collaborative Research Program, Genomic responses in mouse models poorly mimic human in-fl ammatory diseases. Proc. Natl. Acad. Sci. U.S.A. 110, 3507-3512 (2013).
5. K. Takao, T. Miyakawa, Genomic responses in mouse models greatly mimic human infl ammatory diseases. Proc. Natl. Acad. Sci. U.S.A. (2014). 10.1073/pnas.1401965111
6. J. C. Marshall, Why have clinical trials in sepsis failed? Trends Mol. Med. 20, 195-203 (2014).
7. L. C. Casey, R. A. Balk, R. C. Bone, Plasma cytokine and en-dotoxin levels correlate with survival in patients with the sepsis syndrome. Ann. Intern. Med. 119, 771-778 (1993).
8. J. A. Lorente, J. C. Marshall, Neutralization of tumor necrosis factor in preclinical models of sepsis. Shock 24 (suppl. 1), 107-119 (2005).
9. S. M. Opal et al., ACCESS Study Group, Eff ect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: The ACCESS randomized trial. J. Am. Med. Assoc. 309, 1154-1162 (2013).
10. W. S. Dalton, S. H. Friend, Cancer biomarkers-An invitation to the table. Science 312, 1165-1168 (2006).
11. A. Mullard, Cholesterol-lowering blockbuster candidates speed into Phase III trials. Nature Rev. Drug Discov. 11, 817-819 (2012).